CFGS
APLS

Concourse Financial Group Securities’s Apellis Pharmaceuticals APLS Stock Holding History

Concourse Financial Group Securities’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed -$37 – 2247
2024
Q2 		$38 Hold
1
– – ﹤0.01% 2282
2024
Q1 		$58 Hold
1
– – ﹤0.01% 2283
2023
Q4 		$59 Hold
1
– – ﹤0.01% 2250
2023
Q3 		$38 Buy
+1
New +$44 ﹤0.01% 2285

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Concourse Financial Group Securities's APLS Position: Q3 2024 in Review

Concourse Financial Group Securities sold out of Apellis Pharmaceuticals (APLS) in Q3 2024, closing a stake of 1 share — an estimated $37 sold.

Concourse Financial Group Securities first reported a position in APLS in Q3 2023 and held it in 4 quarters. The position peaked at $59 in Q4 2023. 265 funds tracked by Wall St. Rank hold APLS as of Q3 2024.

  • Concourse Financial Group Securities reported no remaining Apellis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Concourse Financial Group Securities sold 1 Apellis Pharmaceuticals share in Q3 2024, an estimated $37.
  • Concourse Financial Group Securities first reported a position in Apellis Pharmaceuticals in Q3 2023 and held it in 4 quarters.
  • Concourse Financial Group Securities's Apellis Pharmaceuticals position peaked at $59 in Q4 2023.
  • 265 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2024.

Based on Concourse Financial Group Securities's 13F filing for Q3 2024, filed 10 Oct 2024.